Stakeholder Opinions: HIV and HCV Co-infection - Whose Niche?

Introduction

The HIV and hepatitis C (HCV) treatment markets are among the fastest growing infectious disease sectors. As co-infection with HIV and HCV is becoming increasingly common, as a result of shared transmission routes, key players are faced with a series of challenges. These include driving compliance rates, overcoming drug interactions, and accessing high risk populations. 

Scope

Key opinion leader insight into treatment strategies for co-infected HIV/HCV patients 

Case studies featuring the leading global players: Roche, GlaxoSmithKline, Boehringer Ingelheim and Gilead 

Key data and detailed epidemiology of HIV and HCV in the seven major markets: the US, Japan, Germany, France, Italy, Spain, and the UK 

Review of current HIV and HCV markets, including key company market share 

Report Highlights

HCV is the most prevalent chronic infection within the HIV cohort, infecting over 30% of HIV positive individuals. However, the HIV/HCV co-infected population is primarily comprised of difficult-to-treat patient groups, such as intravenous drug users (IDUs).  

HIV/HCV patient potential is limited by poor compliance and low prevalence rates, limiting the incentive for novel product development. However, penetration of the co-infected market will enable companies to leverage their products into the wider HIV or HCV mono-infected populations. 

Treatment of HIV/HCV co-infected patients is complicated by drug-drug interactions and the hepatotoxic side effects of certain HIV products. The design and development of a treatment package with proven efficacy in the co-infected population would provide physicians with a convenient treatment strategy.  

Reasons to Purchase

Identification of key co-infected high-risk patient populations will enable companies to design effective targeting strategies 

Evaluation of current treatment practices highlights areas of clinical unmet need and subsequent potential penetration strategies 

Detailed analysis of existing and pipeline products allows identification of opportunities for company collaboration in the co-infection market. 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a212